21/06/2022
Cáncer de mama: la diabetes se asocia con una peor fatiga relacionada con el cáncer
The association between cancer-related fatigue and diabetes from pre-chemotherapy to 6 months post-chemotherapy
Amber S Kleckner 1 , Ian R Kleckner 2 , Eva Culakova 3 , Michelle Shayne 4 , Elizabeth K Belcher 5 , Abdi T Gudina 3 , AnnaLynn M Williams 6 , Adedayo A Onitilo 7 , Judith O Hopkins 8 , Howard Gross 9 , Karen M Mustian 3 , Luke J Peppone 3 , Michelle C Janelsins 10
Affiliations expand
PMID: 35678881 DOI: 10.1007/s00520-022-07189-x
Full text links Cite
Abstract
Purpose: To quantify the relationship between diabetes and fatigue from pre-chemotherapy to 6 months post-chemotherapy for women with breast cancer compared to women without a history of cancer (controls).
Methods: This was a secondary analysis from a nationwide prospective longitudinal study of female patients with breast cancer undergoing chemotherapy and controls. Diabetes diagnosis (yes/no) was obtained at baseline, and cancer-related fatigue was measured using the Multidimensional Fatigue Symptom Inventory (MFSI) pre-, post-, and 6 months post-chemotherapy in patients; controls were assessed at equivalent time points. Repeated measures mixed effects models estimated the association between fatigue and diabetes controlling for cancer (yes/no), body mass index, exercise and smoking habits, baseline anxiety and depressive symptoms, menopausal status, marital status, race, and education.
Results: Among 439 patients and 235 controls (52.8 ± 10.5 years old), diabetes was twice as prevalent among patients as controls (11.6% vs. 6.8%). At baseline, diabetes was associated with worse fatigue (4.1 ± 1.7 points, p = 0.017). Also, diabetes was associated with clinically meaningful worse fatigue throughout the study period among all participants (5.2 ± 1.9 points, p = 0.008) and patients alone (4.5 ± 2.0, p = 0.023). For the MFSI subdomains among patients, diabetes was associated with worse general (p = 0.005) and mental fatigue (p = 0.026).
Conclusions: Diabetes was twice as prevalent in women with breast cancer compared to controls, and diabetes was associated with more severe cancer-related fatigue in patients before and after chemotherapy and at 6 months post-chemotherapy. Interventions that address diabetes management may also help address cancer-related fatigue during chemotherapy treatment.
Trial registration: ClinicalTrials.gov identifier: NCT01382082, first posted June 27, 2011.
Keywords: Cancer-related fatigue; Chemotherapy; Diabetes; Metabolism; Supportive care.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
https://pubmed.ncbi.nlm.nih.gov/35678881/